Yoshiki Katada

Yoshiki Katada

Auto-generated profile, based on publicly available information

Yoshiki Katada

Department of Clinical Pharmacology and Therapeutics Kyoto University Hospital Kyoto Japan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2023 in Transplant Infectious Disease
Verified
Journal Article
Closed access
YKYoshiki Katada
Yoshiki Katada
SNShunsaku Nakagawa
Shunsaku Nakagawa
MNMiki Nagao
Miki Nagao
KUKeisuke Umemura
Keisuke Umemura
KIKotaro Itohara
Kotaro Itohara
TTTomohiro Terada
Tomohiro Terada

18 August 2025 in Clinical and Translational Science
Verified
Journal Article
Open access
YKYoshiki Katada
Yoshiki Katada
DHDaiki Hira
Daiki Hira
KUKeisuke Umemura
Keisuke Umemura
YKYurie Katsube
Yurie Katsube
HIHiroki Ishimura
Hiroki Ishimura
TTTomohiro Terada
Tomohiro Terada
Voriconazole (VRCZ) is a triazole antifungal agent with a broad antifungal spectrum. It is metabolized by hepatic cytochrome P450 (CYP) isozyme CYP2C19, whose genetic polymorphism causes significant variability in drug efficacy and safety. Poor metabolizer alleles of CYP2C19 are more common in Asian populations, increasing the risk of supratherapeutic VRCZ levels. We have developed a novel nomogram based on CYP2C19 genetic polymorphisms. This study aimed to evaluate whether CYP2C19 genotype‐guided VRCZ therapy reduces toxicity in Japanese patients. This retrospective study included 64 patients (genotype‐guided group, n = 26; comparison group, n = 38). The primary outcome was defined as the composite incidence of adverse events commonly observed with VRCZ, represented by the combined occurrence of grade ≥ 2 hepatotoxicity and visual symptoms. Secondary outcomes included the proportion of patients maintaining VRCZ trough concentrations within the therapeutic range (1–4 μg/mL) and the treatment response at 28 days. The composite incidence of adverse events was significantly lower in the genotype‐guided group than in the comparison group (p = 0.003). VRCZ discontinuation due to adverse events occurred in nine patients (23.7%) in the comparison group and one (3.8%) in the genotype‐guided group (p = 0.039). More patients in the genotype‐guided group were achieved through concentrations within the therapeutic range at the initial sampling point. However, treatment response rates did not differ significantly between the groups. VRCZ administration based on CYP2C19 genotyping improved therapeutic trough levels management and reduced adverse effects while maintaining therapeutic efficacy. These findings highlight the importance of CYP2C19 genotyping for VRCZ treatment in Japanese patients.

7 June 2024 in Journal of Pharmaceutical Health Care and Sciences
Verified
Journal Article
Open access
PDF file
YKYoshiki Katada
Yoshiki Katada
KUKeisuke Umemura
Keisuke Umemura
SNShunsaku Nakagawa
Shunsaku Nakagawa
YKYurie Katsube
Yurie Katsube
MTMasahiro Tsuda
Masahiro Tsuda
TTTomohiro Terada
Tomohiro Terada
Background: Ganciclovir and its prodrug, valganciclovir, are first-line agents for cytomegalovirus infection prophylaxis after lung transplantation. Although valganciclovir prophylaxis is known to result in severe leukopenia as an adverse effect, dosage adjustment based on therapeutic drug monitoring (TDM) of ganciclovir concentration is not generally implemented in clinical practice. Case presentation: In this report, we describe the case of a female in her fifties after lung transplantation who successfully maintained valganciclovir prophylaxis under TDM with a minimal occurrence of severe leukopenia. Valganciclovir administration was initiated at a conventional dose of 450 mg/day on postoperative day 43 but was reduced to 450 mg/2 days on postoperative day 69 because of a decrease in white blood cell count and an increase in trough ganciclovir concentration. Subsequently, the valganciclovir dose adjustment was switched from label-indicated renal function-guided dosing to TDM-based dosing, targeting a trough level of 300–800 ng/mL. This target range was determined through deliberations with infectious disease specialists and pharmacists based on previously reported data. The TDM-based dose adjustment successfully prevented cytomegalovirus reactivation without causing significant adverse effects. Valganciclovir prophylaxis was completed on postoperative day 256, and the patient was transferred to another hospital for rehabilitation. Conclusions: The findings of the present case suggest that TDM-based dosing could be helpful for clinicians in optimizing the prophylactic administration of valganciclovir in patients undergoing lung transplantation.

1 January 2022 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
YKYoshiki Katada
Yoshiki Katada
SNShunsaku Nakagawa
Shunsaku Nakagawa
MNMiki Nagao
Miki Nagao
YYYuko Yoshida
Yuko Yoshida
YMYuya Matsuda
Yuya Matsuda
TTTomohiro Terada
Tomohiro Terada

12 February 2024 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
KUKeisuke Umemura
Keisuke Umemura
YKYoshiki Katada
Yoshiki Katada
SNShunsaku Nakagawa
Shunsaku Nakagawa
DHDaiki Hira
Daiki Hira
YYYojiro Yutaka
Yojiro Yutaka
TTTomohiro Terada
Tomohiro Terada

10 July 2024 in Journal of Pharmaceutical Health Care and Sciences
Verified
Journal Article
Open access
PDF file
HNHanako Naganawa
Hanako Naganawa
YKYoshiki Katada
Yoshiki Katada
SNShunsaku Nakagawa
Shunsaku Nakagawa
KUKeisuke Umemura
Keisuke Umemura
HIHiroki Ishimura
Hiroki Ishimura
TTTomohiro Terada
Tomohiro Terada
Background: Among the oral antivirals used for treating patients with mild-to-moderate novel coronavirus disease 2019 (COVID-19), nirmatrelvir/ritonavir (NMV/RTV) and ensitrelvir (ESV) are inhibitors of cytochrome P450 (CYP) 3A, and therefore, can cause drug–drug interactions with concomitant medications. Tacrolimus (TAC), a substrate of CYP3A4/5, is administered for a long period to prevent rejection after kidney transplantation. TAC should be discontinued while using NMV/RTV because blood TAC levels significantly increase when these drugs are concomitantly administered. However, the influence of ESV on blood TAC levels has not yet been reported, and the management of TAC doses during the use of ESV remains unclear. Case presentation: We experienced three kidney transplant recipients with COVID-19, whose blood trough levels of TAC increased by the concomitant use of NMV/RTV or ESV. In two patients administering NMV/RTV, blood trough levels of TAC increased more than tenfold after combination therapy, whereas in one patient administering ESV, TAC level increased approximately threefold. Conclusions: These cases suggest that TAC administration should be discontinued during NMV/RTV treatment to maintain blood TAC levels within the therapeutic range, and a reduced TAC dose is sufficient during ESV treatment.